.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG05_Vedolizumab.Vedolizumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG05_Vedolizumab.Vedolizumab| name: | Vedolizumab |
| ATC code: | L04AG05 | route: | intravenous |
| n-compartments | 2 |
Vedolizumab is a humanized monoclonal antibody that specifically binds to the α4β7 integrin, thereby blocking the interaction with mucosal addressin cell adhesion molecule-1 (MAdCAM-1). It is approved for the treatment of moderately to severely active ulcerative colitis and Crohn's disease in adults, acting as a gut-selective anti-inflammatory agent.
Population pharmacokinetic parameters for vedolizumab in adult patients with moderately to severely active ulcerative colitis or Crohn's disease.
Rosario, M, et al., & Fox, I (2017). A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab. Clinical pharmacokinetics 56(11) 1287–1301. DOI:10.1007/s40262-017-0546-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28523450
Xie, R, et al., & Prokopienko, A (2023). Pharmacokinetics and Safety of Vedolizumab Following Administration of a Single Intravenous Dose in Healthy Chinese Subjects. European journal of drug metabolism and pharmacokinetics 48(1) 35–40. DOI:10.1007/s13318-022-00804-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36400983
D'Haens, G, et al., & Sandborn, WJ (2024). Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis. Expert review of clinical pharmacology 17(4) 403–412. DOI:10.1080/17512433.2024.2318465 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38441048